RxDoctor Payments Data

Lydia Speer, DO

Family Medicine · Chattanooga, TNNPI 1073833364

Payments from drug & device makers

$3,874in general payments, 2019–2025

Across 219 payments — averaging $17.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$660
  • AbbVie$523
  • AstraZeneca$411
  • Pfizer$292
  • Abbott$207
  • Insulet Corporation$144
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$3,874100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,874 in reported general payments places this provider in the 75th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$63,846
Medicare patients
209
Services billed
705

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide166$218,798
OzempicSemaglutide88$161,163
JardianceEmpagliflozin47$82,011
TradjentaLinagliptin34$46,177
EliquisApixaban34$44,533
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$35,500
LinzessLinaclotide20$27,442
Repatha SureclickEvolocumab43$23,560
BelsomraSuvorexant50$23,355
TrulicityDulaglutide17$21,307
FarxigaDapagliflozin Propanediol15$20,582
XareltoRivaroxaban13$18,831
Tresiba Flextouch U-200Insulin Degludec11$15,180
Breo ElliptaFluticasone/Vilanterol26$11,399
MovantikNaloxegol Oxalate13$9,113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$91$240,105183 claims
Novo NordiskOzempic$660$161,16388 claims
Boehringer IngelheimJardiance, Tradjenta$127$128,18881 claims
PfizerEliquis, Premarin$292$51,75556 claims
GSKTrelegy Ellipta, Breo Ellipta$130$46,89965 claims
AbbVieLinzess, Synthroid$523$30,97086 claims
MerckBelsomra$24$23,35550 claims
AstraZenecaFarxiga$411$20,58215 claims
Johnson & JohnsonXarelto$25$18,83113 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$13$5,38712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →